Skip to main content
Erschienen in: Inflammation 2/2016

27.11.2015 | ORIGINAL ARTICLE

2,8-Decadiene-1,10-Diol Inhibits Lipopolysaccharide-Induced Inflammatory Responses Through Inactivation of Mitogen-Activated Protein Kinase and Nuclear Factor-κB Signaling Pathway

verfasst von: Mi-Sun Kim, Eun-Kyung Ahn, Seong Su Hong, Joa Sub Oh

Erschienen in: Inflammation | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Amomum tsao-ko (A. tsao-ko) has been used as a traditional medicine for the treatment of infectious and digestive disorders. In the present study, we report the anti-inflammatory activity and molecular mechanism of 2,8-decadiene-1,10-diol (DDO) isolated from the extract of A. tsao-ko in lipopolysaccharide-stimulated RAW 264.7 cells. DDO treatment inhibited the production of nitric oxide and prostaglandin E2 by downregulating inducible nitric oxide synthase and cyclooxygenase-2 expression, respectively. Moreover, DDO suppressed the production of pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor-α. These inhibitory effects of DDO on the expression of inflammatory proteins were found to be mediated through the inactivation of mitogen-activated protein kinases (MAPKs) such as extracellular signal-regulated kinase, c-Jun-N-terminal kinase and p38MAPK, and inhibition of nuclear factor-κB (NF-κB) pathways including degradation of inhibitor of κB-α and nuclear localization of NF-κB. Taken together, these findings demonstrate the pharmacological roles and molecular mechanisms of DDO in regulating inflammatory responses, and suggest further evaluation and development of DDO as a potent therapeutic agent for the treatment of inflammatory disorders.
Literatur
1.
Zurück zum Zitat Yang, Y., Y. Yue, Y. Runwei, and Z. Guolin. 2010. Cytotoxic, apoptotic and antioxidant activity of the essential oil of Amomum tsao-ko. Bioresource Technology 101: 4205–4211.CrossRefPubMed Yang, Y., Y. Yue, Y. Runwei, and Z. Guolin. 2010. Cytotoxic, apoptotic and antioxidant activity of the essential oil of Amomum tsao-ko. Bioresource Technology 101: 4205–4211.CrossRefPubMed
2.
Zurück zum Zitat Moon, S.S., J.Y. Lee, and S.C. Cho. 2004. Isotsaokoin, an antifungal agent from Amomum tsao-ko. Journal of Natural Products 67: 889–891.CrossRefPubMed Moon, S.S., J.Y. Lee, and S.C. Cho. 2004. Isotsaokoin, an antifungal agent from Amomum tsao-ko. Journal of Natural Products 67: 889–891.CrossRefPubMed
3.
Zurück zum Zitat Yu, L., N. Shirai, H. Suzuki, N. Sugane, T. Hosono, Y. Nakajima, et al. 2010. The effect of methanol extracts of tsaoko (Amomum tsao-ko Crevost et Lemaire) on digestive enzyme and antioxidant activity in vitro, and plasma lipids and glucose and liver lipids in mice. Journal of Nutritional Science and Vitaminology 56: 171–176.CrossRefPubMed Yu, L., N. Shirai, H. Suzuki, N. Sugane, T. Hosono, Y. Nakajima, et al. 2010. The effect of methanol extracts of tsaoko (Amomum tsao-ko Crevost et Lemaire) on digestive enzyme and antioxidant activity in vitro, and plasma lipids and glucose and liver lipids in mice. Journal of Nutritional Science and Vitaminology 56: 171–176.CrossRefPubMed
4.
Zurück zum Zitat Li, B., H.J. Choi, D.S. Lee, H. Oh, Y.C. Kim, J.Y. Moon, et al. 2014. Amomum tsao-ko suppresses lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages via Nrf2-dependent heme oxygenase-1 expression. The American Journal of Chinese Medicine 42: 1229–1244.CrossRefPubMed Li, B., H.J. Choi, D.S. Lee, H. Oh, Y.C. Kim, J.Y. Moon, et al. 2014. Amomum tsao-ko suppresses lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages via Nrf2-dependent heme oxygenase-1 expression. The American Journal of Chinese Medicine 42: 1229–1244.CrossRefPubMed
5.
6.
Zurück zum Zitat Hayden, M.S., A.P. West, and S. Ghosh. 2006. NF-κB and the immune response. Oncogene 25: 6758–6780.CrossRefPubMed Hayden, M.S., A.P. West, and S. Ghosh. 2006. NF-κB and the immune response. Oncogene 25: 6758–6780.CrossRefPubMed
8.
Zurück zum Zitat Ghosh, S., and M.S. Hayden. 2008. New regulators of NF-κB in inflammation. Nature Reviews Immunology 8: 837–848.CrossRefPubMed Ghosh, S., and M.S. Hayden. 2008. New regulators of NF-κB in inflammation. Nature Reviews Immunology 8: 837–848.CrossRefPubMed
9.
Zurück zum Zitat Barnes, P.J., and M. Karin. 1997. Nuclear factor-κB—a pivotal transcription factor in chronic inflammatory diseases. New England Journal of Medicine 336: 1066–1071.CrossRefPubMed Barnes, P.J., and M. Karin. 1997. Nuclear factor-κB—a pivotal transcription factor in chronic inflammatory diseases. New England Journal of Medicine 336: 1066–1071.CrossRefPubMed
10.
11.
Zurück zum Zitat Lumeng, C.N., and A.R. Saltiel. 2011. Inflammatory links between obesity and metabolic disease. The Journal of Clinical Investigation 121: 2111–2117.CrossRefPubMedPubMedCentral Lumeng, C.N., and A.R. Saltiel. 2011. Inflammatory links between obesity and metabolic disease. The Journal of Clinical Investigation 121: 2111–2117.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Ben-Neriah, Y., and M. Karin. 2011. Inflammation meets cancer, with NF-κB as the matchmaker. Nature Immunology 12: 715–723.CrossRefPubMed Ben-Neriah, Y., and M. Karin. 2011. Inflammation meets cancer, with NF-κB as the matchmaker. Nature Immunology 12: 715–723.CrossRefPubMed
14.
Zurück zum Zitat Lizzul, P.F., A. Aphale, R. Malaviya, Y. Sun, S. Masud, V. Dombrovskiy, et al. 2005. Differential expression of phosphorylated NF-κB//RelA in normal and psoriatic epidermis and downregulation of NF-κB in response to treatment with etanercept. Journal of Investigative Dermatology 124: 1275–1283.CrossRefPubMed Lizzul, P.F., A. Aphale, R. Malaviya, Y. Sun, S. Masud, V. Dombrovskiy, et al. 2005. Differential expression of phosphorylated NF-κB//RelA in normal and psoriatic epidermis and downregulation of NF-κB in response to treatment with etanercept. Journal of Investigative Dermatology 124: 1275–1283.CrossRefPubMed
15.
Zurück zum Zitat Gillooly, K.M., M.A. Pattoli, T.L. Taylor, L. Chen, L. Cheng, K.R. Gregor, et al. 2009. Periodic, partial inhibition of IκB kinase β-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis. Journal of Pharmacology and Experimental Therapeutics 331: 349–360.CrossRefPubMed Gillooly, K.M., M.A. Pattoli, T.L. Taylor, L. Chen, L. Cheng, K.R. Gregor, et al. 2009. Periodic, partial inhibition of IκB kinase β-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis. Journal of Pharmacology and Experimental Therapeutics 331: 349–360.CrossRefPubMed
16.
Zurück zum Zitat Ahn, E.K., J.A. Lee, D.W. Seo, S.S. Hong, and J.S. Oh. 2012. 1β-Hydroxy-2-oxopomolic acid isolated from Agrimonia pilosa extract inhibits adipogenesis in 3T3-L1 cells. Biological and Pharmaceutical Bulletin 35: 643–649.CrossRefPubMed Ahn, E.K., J.A. Lee, D.W. Seo, S.S. Hong, and J.S. Oh. 2012. 1β-Hydroxy-2-oxopomolic acid isolated from Agrimonia pilosa extract inhibits adipogenesis in 3T3-L1 cells. Biological and Pharmaceutical Bulletin 35: 643–649.CrossRefPubMed
17.
Zurück zum Zitat Ahn, E.K., and J.S. Oh. 2013. Lupenone isolated from Adenophora triphylla var. Japonica extract inhibits adipogenic differentiation through the downregulation of PPARγ in 3T3-L1 cells. Phytotherapy Research 27: 761–766.CrossRefPubMed Ahn, E.K., and J.S. Oh. 2013. Lupenone isolated from Adenophora triphylla var. Japonica extract inhibits adipogenic differentiation through the downregulation of PPARγ in 3T3-L1 cells. Phytotherapy Research 27: 761–766.CrossRefPubMed
18.
Zurück zum Zitat Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annual Review of Immunology 18: 621–663.CrossRefPubMed Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annual Review of Immunology 18: 621–663.CrossRefPubMed
19.
Zurück zum Zitat Vermeulen, L., G. De Wilde, P. Van Damme, W. Vanden Berghe, and G. Haegeman. 2003. Transcriptional activation of the NF-κB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). The EMBO Journal 22: 1313–1324.CrossRefPubMedPubMedCentral Vermeulen, L., G. De Wilde, P. Van Damme, W. Vanden Berghe, and G. Haegeman. 2003. Transcriptional activation of the NF-κB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). The EMBO Journal 22: 1313–1324.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Carter, A.B., K.L. Knudtson, M.M. Monick, and G.W. Hunninghake. 1999. The p38 mitogen-activated protein kinase is required for NF-κB-dependent gene expression: the role of TATA-binding protein (TBP). Journal of Biological Chemistry 274: 30858–30863.CrossRefPubMed Carter, A.B., K.L. Knudtson, M.M. Monick, and G.W. Hunninghake. 1999. The p38 mitogen-activated protein kinase is required for NF-κB-dependent gene expression: the role of TATA-binding protein (TBP). Journal of Biological Chemistry 274: 30858–30863.CrossRefPubMed
21.
Zurück zum Zitat Kim, H.J., H.S. Lee, Y.H. Chong, and J.L. Kang. 2006. p38 mitogen-activated protein kinase up-regulates LPS-induced NF-κB activation in the development of lung injury and RAW 264.7 macrophages. Toxicology 225: 36–47.CrossRefPubMed Kim, H.J., H.S. Lee, Y.H. Chong, and J.L. Kang. 2006. p38 mitogen-activated protein kinase up-regulates LPS-induced NF-κB activation in the development of lung injury and RAW 264.7 macrophages. Toxicology 225: 36–47.CrossRefPubMed
22.
Zurück zum Zitat Zandi, E., D.M. Rothwarf, M. Delhase, M. Hayakawa, and M. Karin. 1997. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell 91: 243–252.CrossRefPubMed Zandi, E., D.M. Rothwarf, M. Delhase, M. Hayakawa, and M. Karin. 1997. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell 91: 243–252.CrossRefPubMed
23.
Zurück zum Zitat Delhase, M., M. Hayakawa, Y. Chen, and M. Karin. 1999. Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation. Science 284: 309–313.CrossRefPubMed Delhase, M., M. Hayakawa, Y. Chen, and M. Karin. 1999. Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation. Science 284: 309–313.CrossRefPubMed
24.
Zurück zum Zitat Guha, M., and N. Mackman. 2001. LPS induction of gene expression in human monocytes. Cellular Signalling 13: 85–94.CrossRefPubMed Guha, M., and N. Mackman. 2001. LPS induction of gene expression in human monocytes. Cellular Signalling 13: 85–94.CrossRefPubMed
25.
Zurück zum Zitat Bode, J.G., C. Ehlting, and D. Häussinger. 2012. The macrophage response towards LPS and its control through the p38MAPK–STAT3 axis. Cellular Signalling 24: 1185–1194.CrossRefPubMed Bode, J.G., C. Ehlting, and D. Häussinger. 2012. The macrophage response towards LPS and its control through the p38MAPK–STAT3 axis. Cellular Signalling 24: 1185–1194.CrossRefPubMed
26.
Zurück zum Zitat Hommes, D.W., M.P. Peppelenbosch, and S.J.H. van Deventer. 2003. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 52: 144–151.CrossRefPubMedPubMedCentral Hommes, D.W., M.P. Peppelenbosch, and S.J.H. van Deventer. 2003. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 52: 144–151.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Karin, M. 2006. Nuclear factor-κB in cancer development and progression. Nature 441: 431–436.CrossRefPubMed Karin, M. 2006. Nuclear factor-κB in cancer development and progression. Nature 441: 431–436.CrossRefPubMed
Metadaten
Titel
2,8-Decadiene-1,10-Diol Inhibits Lipopolysaccharide-Induced Inflammatory Responses Through Inactivation of Mitogen-Activated Protein Kinase and Nuclear Factor-κB Signaling Pathway
verfasst von
Mi-Sun Kim
Eun-Kyung Ahn
Seong Su Hong
Joa Sub Oh
Publikationsdatum
27.11.2015
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 2/2016
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-015-0283-1

Weitere Artikel der Ausgabe 2/2016

Inflammation 2/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.